Verma, Subodh

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial

Crowley, M. J., McGuire, D. K., Alexopoulos, A.-S., Jensen, T. J., Rasmussen, S., Saevereid, H. A., Verma, S., & Buse, J. B. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 47

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity

Mentias, A., Desai, M. Y., Aminian, A., Patel, K. V., Keshvani, N., Verma, S., Cho, L., Jacob, M., Alvarez, P., Lincoff, A. M., et al. (2024) · Circulation: Heart Failure

Bariatric Surgery and OutcomesHeart Failure Treatment and Management

Cited by 40

Optimal screening for predicting and preventing the risk of heart failure among adults with diabetes without atherosclerotic cardiovascular disease: a pooled cohort analysis

Patel, K. V., Segar, M. W., Klonoff, D. C., Khan, M. S., Usman, M. S., Lam, C. S. P., Verma, S., DeFilippis, A. P., Nasir, K., Bakker, S. J. L., et al. (2024) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 38

Impact of diabetes on carotid artery revascularization

Hussain, M. A., Bin-Ayeed, S. A., Saeed, O. Q., Verma, S., & Al-Omran, M. (2016) · Journal of Vascular Surgery

Cerebrovascular and Carotid Artery DiseasesAcute Ischemic Stroke Management

Cited by 37

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use: Results From the LEADER Trial

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach

Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 32

Sodium‐Glucose Cotransporter 2 Inhibitors, All‐Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta‐Analysis and Meta‐Regression

Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 29

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction

Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 24

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes

Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 23

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide

Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 17

Abstract 4139912: Inflammatory biomarkers in people treated with tirzepatide living with overweight or obesity, without and with T2D: a post-hoc analysis from SURMOUNT-1 and SURMOUNT-2

Sattar, N., Verma, S., Sourij, H., Wilson, J., Stefanski, A., zhang, X., Griffin, R., Ruotolo, G., & Linetzky, B. (2024) · Circulation

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 10